 Sinopharm, Chinas large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50 owned by Sinopharm. Shanghais SciNeuro Pharma in-licensed Greater China rights to Lillys alpha-synuclein targeted antibody therapies, an expected therapy for Parkinsons. 